Revolution Medicines Stock Alpha and Beta Analysis
| RVMD Stock | USD 102.74 2.95 2.96% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Revolution Medicines. It also helps investors analyze the systematic and unsystematic risks associated with investing in Revolution Medicines over a specified time horizon. Remember, high Revolution Medicines' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Revolution Medicines' market risk premium analysis include:
Beta (0.23) | Alpha 0.81 | Risk 4.86 | Sharpe Ratio 0.14 | Expected Return 0.67 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Revolution | Build AI portfolio with Revolution Stock |
Revolution Medicines Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Revolution Medicines market risk premium is the additional return an investor will receive from holding Revolution Medicines long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Revolution Medicines. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Revolution Medicines' performance over market.| α | 0.81 | β | -0.23 |
Revolution Medicines expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Revolution Medicines' Buy-and-hold return. Our buy-and-hold chart shows how Revolution Medicines performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Revolution Medicines Market Price Analysis
Market price analysis indicators help investors to evaluate how Revolution Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Revolution Medicines shares will generate the highest return on investment. By understating and applying Revolution Medicines stock market price indicators, traders can identify Revolution Medicines position entry and exit signals to maximize returns.
Revolution Medicines Return and Market Media
The median price of Revolution Medicines for the period between Sat, Nov 22, 2025 and Fri, Feb 20, 2026 is 80.58 with a coefficient of variation of 18.15. The daily time series for the period is distributed with a sample standard deviation of 16.28, arithmetic mean of 89.67, and mean deviation of 14.29. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Revolution Medicines Assessing Valuation After a Powerful MultiYear Share Price Run-Up | 12/11/2025 |
2 | Disposition of 3104 shares by Jack Anders of Revolution Medicines at 77.0904 subject to Rule 16b-3 | 12/16/2025 |
3 | Disposition of 51406 shares by Horn Margaret A of Revolution Medicines at 42.45 subject to Rule 16b-3 | 01/02/2026 |
4 | Merck in Talks to Buy Revolution Medicines Per Financial Times Report | 01/09/2026 |
5 | Disposition of 908 shares by Cislini Jeff of Revolution Medicines at 115.6 subject to Rule 16b-3 | 01/21/2026 |
6 | Jim Cramer Highlights Takeover Interest in Revolution Medicines | 01/22/2026 |
7 | Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit | 01/26/2026 |
8 | Why Revolution Medicines Stock Plummeted by Almost 17 percent Today | 01/27/2026 |
9 | Y Intercept Hong Kong Ltd Has 2.58 Million Stock Position in Revolution Medicines, Inc. RVMD | 01/28/2026 |
10 | Did RMC-5127s First-in-Human Trial Launch Just Shift Revolution Medicines Investment Narrative | 02/02/2026 |
11 | Revolution Medicines, Inc. Receives Average Recommendation of Buy from Brokerages - MarketBeat | 02/05/2026 |
12 | First-in-Human RMC-5127 Trial Could Be A Game Changer For Revolution Medicines | 02/09/2026 |
13 | Revolution Medicines, Inc. RVMD Shares Sold by Allianz Asset Management GmbH - MarketBeat | 02/12/2026 |
14 | Is Revolution Medicines Pricing In Pipeline Progress After A 135.7 percent One Year Surge | 02/19/2026 |
About Revolution Medicines Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Revolution or other stocks. Alpha measures the amount that position in Revolution Medicines has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2025 | 2026 (projected) | Days Sales Outstanding | 39.53 | 45.45 | 75.46 | PTB Ratio | 1.78 | 3.72 | 3.54 |
Revolution Medicines Upcoming Company Events
As portrayed in its financial statements, the presentation of Revolution Medicines' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revolution Medicines' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Revolution Medicines' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Revolution Medicines. Please utilize our Beneish M Score to check the likelihood of Revolution Medicines' management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Revolution Medicines
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Revolution Medicines Analysis, Revolution Medicines Valuation, Revolution Medicines Correlation, Revolution Medicines Hype Analysis, Revolution Medicines Volatility, Revolution Medicines Price History and analyze Revolution Medicines Performance. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Revolution Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.